

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

1721-112

SERIAL NO.

 Unknown; Natl. Phase of
PCT/FR2004/002422

APPLICANT

JACOTOT ET AL.

(Use several sheets if necessary)

FILING DATE

March 24, 2006

TC/A.U.

Unknown

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
00/49038	8/2000	WO			
01/92542	12/2001	WO			
2004/031768	4/2004	WO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	International Search Report for PCT/FR2004/002422 dated 18 February 2005.
	Kawaguchi et al., <i>A novel synthetic Arg-Gly-Asp-containing peptide cyclo(-RGDfbdV-) is the potent inhibitor of angiogenesis</i> , Biochemical and Biophysical Research Communications, vol. 288, no. 3, 2 November 2001, pp. 711-717, XP002274582.
	Kumar, <i>Integrin alphavbeta3 as a therapeutic target for blocking tumor-induced angiogenesis</i> , Current Drug Targets, vol. 4, no. 2, February 2003, pp. 123-131, XP0009027835.
	Westlin, <i>Integrins as targets of angiogenesis inhibition</i> , Cancer Journal, 2001 Nov-Dec, vol. 7 Suppl. 3, November 2001, pp. S139-S143, XP0009027919.
	Ruegg et al., <i>Vascular integrins: Pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis</i> , CMLS Cellular and Molecular Life Sciences, vol. 60, no. 6, June 2003, pp. 1135-1157, XP0001180259.
	Costantini et al., <i>Mitochondrion as a novel target of anticancer chemotherapy</i> , Journal of the National Cancer Institute, 5 July 2000, vol. 92, no. 13, 5 July 2000, pp. 1042-1053, XP0009008236.
	Schraa Astrid et al., <i>Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting</i> , Journal of Controlled Release: Official Journal of the Controlled Release Society, 4 October 2002, vol. 83, no. 2, 4 October 2002, pp. 241-251, XP0004383634.
	Haubner et al., <i>Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the alphavbeta3 integrin for a new cancer therapy</i> , Angewandte Chemie. International Edition, vol. 36, 1997, pp. 1375-1389, XP001008836.

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.